The present invention relates to the use of a compound of general formula (I) wherein R/R are independently from each other hydrogen, lower alkyl, -CH)-cycloalkyl for o being 0 or 1, or are benzyl or heterocycloalkyl； or R and R are together with the N-atom to which they are attached a ring containing -(CH)-, -(CH)-, -(CH)-, -(CH)-O-(CH)-, -(CH)-S-(CH)-, -(CH)-NR-(CH)-, -(CH)-C(O)-(CH)-, -(CH)-CF-(CH)-, -CH-CHR-(CH), -CHR-(CH), CHR-(CH)-CHR-, or is the ring 2,6-diaza-spiro[3.3]heptane-2-carboxylic acid tert-butyl ester and R is hydroxy, halogen, cycloalkyl, or C(O)O-lower alkyl； X is -(CH)-, -(CH)-, -(CH)- or -CH-； R is S-lower alkyl, CF, OCHF, lower alkoxy, lower alkyl, phenyl, cycloalkyl or halogen； R is CF, lower alkoxy, lower alkyl, halogen and n is 1 or 2； or to a pharmaceutically acceptable acid addition salt, to a racemic mixture, or to its corresponding enantiomers and/or optical isomers thereof for the manufacture of a medicament for the treatment of psychoses, pain, dysfunction in memory and learning, attention deficit, schizophrenia, dementia disorders or Alzheimer's disease.
